PregnanTech

Preventing preterm birth. Saving lives.

PregnanTech has developed a groundbreaking new medical device for the prevention of preterm birth. Preterm birth is the most common, catastrophic, and costly complication of pregnancy and the leading cause of infant death and illness worldwide.
47 Days to go

50% of funding target

$25,000

Minimum investment
Investment type:
Company Stage:
Category:
Medical Devices

Highlights

Highlights

     


Pitch

Pitch

    

Team

Team

Dr. David Shashar
CEO and Founder
Dr. Shashar graduated from the Hebrew University Medical School and completed his training in Obstetrics and Gynecology at the Sheba Medical Center at Tel Hashomer. David also holds a Master‘s Degree in medical engineering from the Technion and an MBA from Tel Aviv University. He has extensive experience in leading collaborations between physicians, engineers and business experts from the Israeli academia and industry in developing innovative technological solutions for unmet medical needs.
Steve Rhodes
Director
Mr. Rhodes is the chairman and founder of The Trendlines Group. Steve holds a BA from Harvard University and an MBA from the University of Chicago. He has extensive investment experience and serves as a director in many of Trendlines‘ portfolio companies. Mr. Rhodes has years of management experience, including in-depth understanding of financial and organizational requirements for commercial exploitation of start-up companies. He has been involved in dozens of successful negotiations with strategic partners and distributors in the medical device industry.
Ms. Buffy Alegria
Ms. Alegria is a Femtech financial entrepreneur, angel investor, advisor, mentor, and venture capitalist. Her professional background includes numerous roles in corporate banking, risk management and project management in healthcare. Buffy is a Managing Partner of SteelSky Ventures LLC and serves on the board of the Virginia Mason Memorial Hospital and the Washington State Hospital Association. She earned an MST from Oregon Graduate Institute of Science & Technology and BS in Psychology & Biology from Pacific University.
Nir Lilach
Development Manager
Mr. Lilach has over 20 years of experience in leading medical projects from concept to the manufacture of a final product. Nir serves as partner at Eliachar Technologies Development, which specializes in the development of technological products for the medical sector. Nir has a degree in industrial design from IED – Istituto Europeo di Design.
Dr. Helena Grinberg-Rashi
Regulatory Manager
Dr. Grinberg-Rashi holds a PhD in Molecular Medicine and Human Genetics and an MBA from IDC. She is a senior consultant in clinical development and global regulations for medical device companies, digital health technologies, pharma and bio technologies. Helena is the owner of HGR consulting services and her rich experience is utilized for the formulating PregnanTech‘s clinical & regulatory strategy.

Financial data

Financial data

Updates

Updates

Currently there are no updates in this pitch

The financing rounds, made through the ExitValley platform, are in accordance with a model of statutory exemption from publishing a prospectus pursuant to sections 15A(A)(1) and 15A(A)(7) of the Israeli Securities Law - 1968.
Under this model, the disclosure of detailed information on the company and information about the investment in each round of financing are limited to not more than 35 investors, who are not qualified investors, and the round of financing is not in the format of an offering arrangement ("רכז הצעה"), as defined in the Securities Law.
Follow us